Clinical trials: Obesity Overweight
Fatty Liver, Non-Alcoholic Steatohepatitis
A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic…
- Conditions
- Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
- Trial name
- Aramchol_005 (NCT02279524)
- Testing
- Aramchol
- Where
- 78 sites in United States, Chile and 9 more
- Volunteers
- 247 people
- Sponsor
- Galmed Research and Development, Ltd.
Obesity
A Study of BGM0504 in Participants With Obesity
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
- Trial name
- NCT06911203
- Testing
- BGM0504, Tirzepatide
- Where
- China
- Volunteers
- 96 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Psoriasis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and…
- Trial name
- TOGETHER-PsO (NCT06588283)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Obesity
Safety and Effectiveness of Orbera365™ Intragastric Balloon System
This is a prospective, multi-center, standard of care registry offered to subjects in the EU only that have already agreed to receive the Orbera365™ Intragastric Balloon (IGB) System for weight loss.
- Trial name
- Orbera365 (NCT07062094)
- Testing
- Intragastric Balloon
- Where
- 4 sites in Czechia, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Adults With Overweight/Obesity and Type 2 Diabetes
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes.
- Trial name
- NCT07724340
- Testing
- AT673 low dose, AT673 high dose
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Antag Therapeutics
Obesity
Transoral Gastric Volume Reduction as an Intervention for Weight Management
The purpose of this study is to evaluate the safety, technical feasibility, and initial effectiveness (i.e., weight loss primarily measured as percent excess weight loss) of TGVR performed using the Bard RESTORe Suturing System
- Trial name
- TRIM (NCT00679848)
- Testing
- RS2 (RESTORe Suturing System)
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- C. R. Bard
Obesity
Injection Site Pain Comparison of Excipient Solutions
The purpose of this study is to investigate different solutions used to inject drugs under the skin. The solutions used in the study do not contain the drugs they will be used for, but they do contain excipients, which are…
- Trial name
- NCT04482725
- Testing
- Trial product 1, Trial product 2, Trial product 3
- Where
- Netherlands
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Multicenter Study for Pre-Surgical Weight Loss
The purpose of the study is to evaluate the safety and initial efficacy of the EndoBarrier device compared to a diet control in patients who require weight loss prior to their Bariatric surgery.
- Trial name
- NCT00830440
- Testing
- EndoBarrier Device, Diet & Lifestyle Counseling
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Morphic Medical Inc.
Overweight, Obesity
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity.
- Trial name
- NCT04012255
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of multiple subcutaneous injections of GZR18 Injection on the pharmacokinetics of multiple oral doses of metformin hydrochloride…
- Trial name
- NCT06670209
- Testing
- GZR18 and metformin
- Volunteers
- 32 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Obesity
Weight Loss in Pre-diabetic, Obese Women
This is a six (6) month, single center, randomized, double-blind, parallel, controlled-feeding weight-loss study comparing two dietary groups (triglyceride and olestra) in pre-diabetic obese women.
- Trial name
- NCT00686816
- Testing
- Low calorie diet, Olestra
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Procter and Gamble
Obesity
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
- Trial name
- NCT00112021
- Testing
- pramlintide acetate
- Where
- 21 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Obesity, Overweight and Obesity
Investigation of the Effects of a Bifidobacterium Breve Strain on Fat Loss in Healthy Adults
Overweight has become a critical issue in North America and the market value of weight loss products is expected to rise as the population becomes more health-conscious and aware of the risks associated with excess body weight.
- Trial name
- NCT04677738
- Testing
- B. breve strain
- Where
- Canada
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Morinaga Milk Industry Co., LTD
Obesity, Weight Loss
Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects
The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.
- Trial name
- NCT00645255
- Volunteers
- 466 people
- Sponsor
- Abbott
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Obesity, Overweight
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2…
- Trial name
- NCT07765511
- Testing
- Macupatide, Eloralintide
- Where
- 3 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Obesity or Overweight
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week.
- Trial name
- NCT05813925
- Testing
- Cagrilintide, Semaglutide
- Where
- 28 sites in Japan, Taiwan
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
- Conditions
- Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- ENLIGHTEN-10 (NCT07900633)
- Testing
- Eloralintide
- Where
- 309 sites in United States, Argentina and 19 more
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Abdominal Obesity
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
Dose-ranging, randomized, double-blind, vehicle-controlled study
- Trial name
- NCT05422378
- Testing
- STP705
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sirnaomics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.